198 Early experience with neoadjuvant immunochemotherapy and it's safety and efficacy
We present our early experience of operated patients following introduction of this pathway at our unit. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Karishma Chandarana, Ria Bhandhari, Adnan Raza, Mehmood Jadoon, Mohammad Hawari, Nathan Burnside Tags: Surgery Source Type: research
199 Pulmonary plemorphic carcinoma: high PD-L1 expression and other clinicopathologic features of 48 resection cases
Pleomorphic carcinoma is a non-small cell lung cancer, containing at least 10% spindle and/or giant cells, or a carcinoma which consists entirely of these cells. We aimed to analyse the clinicopathologic characteristics of our lung resection cases for this rare malignancy. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Murat Kapdagli, Abu Farmidi, Nizar Asadi, Jonathan Finch, Emma Beddow, Vladimir Anikin Tags: Surgery Source Type: research
200 Comparative analysis of perioperative outcomes in VATS and RATS lung resections: a retrospective audit
The objectives were to assess the differences in postoperative haemoglobin drop, duration of air leak, duration of hospital stay, and postoperative complications between VATS and RATS procedures. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Michael Otorkpa, Syed Qadri, Salman Arif Tags: Surgery Source Type: research
201 Is Segmentectomy Really Enough in all the Different Subtypes of Stage I Adenocarcinoma? A SEER Database Analysis
To compare lobectomy and segmentectomy among different subtypes of stage I lung adenocarcinoma (ADC). (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Pradeep Wijerathne, John Edwards, Ashok Kar, Jagan Rao, Sara Tenconi, Luigi Ventura Ventura Tags: Surgery Source Type: research
202 Retrospective analysis of rate of recurrence in Non Small Cell Lung Cancer (NSCLC) patient treated with curative surgery
Surgery in early-stage NSCLC offers the highest chances of long-term survival. However, recurrence is a real concern [1]. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Jayeeta Dutta, Yadee Myint, Alison Mcmillan, Thida Win Tags: Surgery Source Type: research
203 Should interactive 3D-CT models be used as an alternative to repeat contrast computed tomography in lung cancer screening programme patients for surgical planning?
This study aims to compare nodule sizes between LDCTs and repeat CCTs and assess 3D-CT models obtained from LDCTs versus CCTs to determine whether 3D-CT models from LDCTs are a viable alternative to repeat CCTs. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Kofi James Ackah, Mohammad Diab, Karen Elbrow, Esthew Lewis, Adrian Marchbank Tags: Surgery Source Type: research
204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design
Standard 2-year regimens for anti-PD1 agents nivolumab and pembrolizumab may represent excessive treatment because of high target affinity and prolonged PD1 receptor occupation even after discontinuation. Moreover, these agents exhibit a flat dose-response relationship across a wide dose range. Consequently, lower or less frequent doses may retain efficacy whilst reducing toxicity and improving quality-of-life (QOL). Classical, 2-arm non-inferiority designs are inefficient as they only test one reduced dose or prolonged frequency verses control. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Ehsan Ghorani, Matteo Quartagno, Fiona Blackhall, Mary O'Brien, Christian Ottensmeier, Elena Pizzo, James Spicer, Duncan Gilbert, Alex Baker, Philip Badman, Charlotte Milner-Watts, Paolo D. d'Arienzo, Adam Dangoor, Jason Adhikaree, Joanne Evans, Pollyanna Tags: Trials in progress Source Type: research
205 An update on the VIGILANCE study: Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer
Multi-modality radiotherapy-based treatments are available to treat patients with stage III non-small cell lung cancer and are associated with improved clinical outcomes. However, not all patients benefit from these complex treatments and there is a paucity of biomarkers supporting treatment decisions tailored to the individual patient. The VIGILANCE study's primary aim is to build a prognostic model using longitudinal novel health technology data collected before, during and for 1 year after completion of radiotherapy in patients with stage III non-small cell lung cancer. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Ashley Home, Harry Crawford, Clare Dempsey, Corinne Faivre-Finn Tags: Trials in progress Source Type: research
206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
Osimertinib, a potent, third-generation, oral EGFR-TKI is the preferred first-line treatment in EGFRm advanced NSCLC. However, tumours eventually develop resistance and METoverexpression and/or amplification is the most common acquired resistance mechanism. Savolitinib is an oral, potent, and highly selective MET-TKI. Savolitinib +osimertinib has been investigated in the Ph1B TATTON (NCT02143466)/Ph2 SAVANNAH (NCT03778229) studies. SAFFRON (NCT05261399) aims to assess efficacy/safety of savolitinib+osimertinib vs platinum-based chemotherapy in adult patients with EGFRm, MET-overexpressed and/or -amplified, locally advanced...
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Colin Lindsay, Wanning Xu, Aino Telaranta-Keerie, Nan Jia, Ryan J Hartmaier, Shun Lu Tags: Trials in progress Source Type: research
207 Exploring the experiences of rural and coastal people with lung cancer and their informal carers' in accessing and engaging in treatment: A qualitative interview study
There are wide variations and inequalities in lung cancer care across the UK, but most research has focused on improving the quality of clinical services and less on individual-related factors. There is evidence to suggest that rural people with lung cancer may experience unique inequalities in care compared to their urban counterparts. Lincolnshire has some of the most deprived parts of the UK, particularly in rural and coastal areas, where people face considerable barriers to engaging with, and accessing cancer care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Samuel Cooke, Lucy Mitchinson, Daisy McInnerney, Samantha L Quaife, Zara Pogson, Dawn Skinner, Sarah Civello, Ava Harding-Bell, Ros Kane, Lynn Calman, Peter Selby, Adam Januszewski, Maria Lapuente, Annie Reeves, William Ricketts, Brian Knowles, Michael D Tags: Trials in progress Source Type: research
208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma
Mesothelioma is a rare cancer caused by exposure to asbestos typically affecting the pleura or pericardium. Prognosis remains dismal yet targeted therapies are lacking. Advances have revealed a preponderance of tumour suppressors in mesothelioma, which may present new opportunities to develop treatments. The SELECTmeso trial platform, coordinated by the Cancer Research UK Southampton Clinical Trials Unit, has been developed to leverage new insights into synthetic lethal biology to improve treatment outcomes. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Kayleigh Hill, Dean Fennell, Anna Song, Robin Wickens, Judith Cave, Andrea Corkhill, Jens Hahne, Michelle Lattimore, Peter Wells-Jordan, Nada Nusrat, Sean Dulloo, Charlotte Poile, Gareth Griffiths Tags: Trials in progress Source Type: research
209 ThOracic Umbrella RadIotherapy STudy in stage IV NSCLC: TOURIST
Palliative radiotherapy is widely used in stage IV non-small cell lung cancer (NSCLC). Radiotherapy dose fractionation studies have shown its utility in symptom control with improved survival at higher doses. Recent advances in radiotherapy planning and delivery offer dose escalation while reducing toxicity. However, there are no studies testing palliative radiotherapy in combination with modern systemic therapies and trials are needed to test timing, dose and fractionation in that context. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: David Woolf, Nichola Downs, Chris Sutton, Andrea Corkhill, Izabella Eberhart, Siva Saranya, Kayleigh Hill, Sean Ewings, Gabriel Rogers, Lynn Calman, Amy Hancock, Merina Ahmed, Janette Rawlinson, Jacqui Gath, Caroline Lee, Crispin Hiley, Gareth Griffiths, Tags: Trials in progress Source Type: research
210 If at first you don't succeed …switching treatments in NTRK fusion NSCLC
We describe a young patient treated with NTRK inhibitors with a remarkable response, albeit requiring a drug switch due to severe hepatotoxicity. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Deborah Scott, Tom Geldart Tags: Case Reports Source Type: research
211 The impact of the flu vaccine on fluid volumes in a patient with mesothelioma
A 78-year-old woman with end stage chronic obstructive pulmonary disease and a right pleural mesothelioma had an indwelling pleural catheter (IPC) in situ for control of her malignant effusion. She was for best supportive care. Serous, yellow fluid was drained 2 –3 times a week, volumes averaged 150–200 mls. The patient underwent influenza vaccination as part of yearly routine primary care. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Leah Taylor, Helen Wallace, Avinash Aujayeb Tags: Case Reports Source Type: research
212 Incidence and Outcomes of MRI-confirmed Myocarditis in Patients Receiving Immune Checkpoint Inhibitors for Lung Cancer - A Single Tertiary Centre Experience
Myocarditis is a rare and life-threatening complication of immune checkpoint inhibitors (ICI). Lung cancer patients present a diagnostic conundrum with overlapping symptoms, co-morbidities, treatment toxicity, and tumour burden. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Alfred So, Arjun K Ghosh, Charlotte Manisty, Adam Januszweski Tags: Case Reports Source Type: research
